4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer
Sponsor: M.D. Anderson Cancer Center
Terminated
Slow accrual.
Other terminated trials from M.D. Anderson Cancer Center
- Acute Lymphoblastic Leukemia · Apr 2026
- Brain Neoplasm · Apr 2026
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Apr 2026
- Breast Cancer Survivor · Apr 2026
- Acute Myeloid Leukemia · Phase PHASE2 · Mar 2026
More terminations from M.D. Anderson Cancer Center
Other Head and Neck Cancer trials with similar outcome
Listed as NCT00102635, this PHASE1 trial focuses on Head and Neck Cancer and remains terminated or withdrawn. Sponsored by M.D. Anderson Cancer Center, it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Dec 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Dec 2018 [monthly]
Terminated PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Jan 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
- Schering-Plough
For direct contact, visit the study record on ClinicalTrials.gov .